The Edwards Lifesciences Corp. (EW) Position Lowered by Partner Investment Management L.P.

The Edwards Lifesciences Corp. (EW) Position Lowered by Partner Investment Management L.P.

Partner Investment Management L.P. decreased its stake in Edwards Lifesciences Corp. (NYSE:EW) by 13.2% during the third quarter, according to its most recent 13F filing with the SEC. The firm owned 19,693 shares of the medical research company’s stock after selling 2,990 shares during the period. Edwards Lifesciences Corp. comprises about 3.5% of Partner Investment Management L.P.’s portfolio, making the stock its 3rd largest position. Partner Investment Management L.P.’s holdings in Edwards Lifesciences Corp. were worth $2,374,000 as of its most recent filing with the SEC.

A number of other institutional investors have also added to or reduced their stakes in the company. FMR LLC raised its stake in shares of Edwards Lifesciences Corp. by 1.2% in the second quarter. FMR LLC now owns 12,366,588 shares of the medical research company’s stock valued at $1,233,319,000 after buying an additional 141,713 shares during the period. BlackRock Institutional Trust Company N.A. raised its stake in shares of Edwards Lifesciences Corp. by 1.5% in the third quarter. BlackRock Institutional Trust Company N.A. now owns 5,542,619 shares of the medical research company’s stock valued at $668,218,000 after buying an additional 81,691 shares during the period. BlackRock Fund Advisors raised its stake in shares of Edwards Lifesciences Corp. by 3.4% in the third quarter. BlackRock Fund Advisors now owns 4,337,584 shares of the medical research company’s stock valued at $522,939,000 after buying an additional 143,348 shares during the period. Ameriprise Financial Inc. raised its stake in shares of Edwards Lifesciences Corp. by 1.6% in the third quarter. Ameriprise Financial Inc. now owns 4,320,603 shares of the medical research company’s stock valued at $520,896,000 after buying an additional 66,627 shares during the period. Finally, Northern Trust Corp raised its stake in shares of Edwards Lifesciences Corp. by 0.7% in the third quarter. Northern Trust Corp now owns 2,620,280 shares of the medical research company’s stock valued at $315,902,000 after buying an additional 19,503 shares during the period. Institutional investors own 82.79% of the company’s stock.

Shares of Edwards Lifesciences Corp. (NYSE:EW) traded up 0.52% during trading on Thursday, reaching $96.29. 2,058,776 shares of the company’s stock were exchanged. Edwards Lifesciences Corp. has a 52-week low of $75.24 and a 52-week high of $121.75. The company has a 50 day moving average price of $91.77 and a 200-day moving average price of $104.56. The company has a market capitalization of $20.59 billion, a PE ratio of 38.06 and a beta of 0.62.

Edwards Lifesciences Corp. (NYSE:EW) last announced its earnings results on Tuesday, October 25th. The medical research company reported $0.68 EPS for the quarter, hitting the consensus estimate of $0.68. The firm had revenue of $739.40 million for the quarter, compared to the consensus estimate of $749.14 million. Edwards Lifesciences Corp. had a net margin of 19.24% and a return on equity of 24.32%. The business’s quarterly revenue was up 20.1% on a year-over-year basis. During the same quarter last year, the firm posted $0.54 EPS. On average, equities analysts forecast that Edwards Lifesciences Corp. will post $2.87 earnings per share for the current year.

Several equities research analysts have recently commented on the company. Stifel Nicolaus decreased their price target on Edwards Lifesciences Corp. from $122.00 to $114.00 and set a “buy” rating on the stock in a research note on Wednesday, October 26th. Royal Bank Of Canada decreased their price target on Edwards Lifesciences Corp. from $130.00 to $123.00 and set an “outperform” rating on the stock in a research note on Wednesday, October 26th. Leerink Swann reaffirmed an “outperform” rating and issued a $130.00 target price on shares of Edwards Lifesciences Corp. in a research note on Friday, October 28th. BTIG Research reaffirmed a “buy” rating and issued a $110.00 target price on shares of Edwards Lifesciences Corp. in a research note on Friday, October 28th. Finally, Vetr lowered Edwards Lifesciences Corp. from a “strong-buy” rating to a “buy” rating and set a $106.00 target price on the stock. in a research note on Tuesday, January 3rd. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and twenty-two have issued a buy rating to the company’s stock. Edwards Lifesciences Corp. currently has an average rating of “Buy” and a consensus target price of $116.96.

In other news, VP Larry L. Wood sold 13,258 shares of the business’s stock in a transaction dated Thursday, December 1st. The shares were sold at an average price of $81.85, for a total transaction of $1,085,167.30. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, VP Catherine M. Szyman acquired 12,870 shares of the company’s stock in a transaction dated Wednesday, November 30th. The shares were bought at an average price of $83.43 per share, for a total transaction of $1,073,744.10. The disclosure for this purchase can be found here. In the last quarter, insiders purchased 65,870 shares of company stock worth $1,334,134 and sold 278,935 shares worth $25,391,347. Company insiders own 2.37% of the company’s stock.

About Edwards Lifesciences Corp.

Edwards Lifesciences Corporation is focused on technologies that treat structural heart disease and critically ill patients. The Company manufactures heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. It develops hemodynamic monitoring systems used to measure a patient’s cardiovascular function in the hospital setting.

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corp. (NYSE:EW).

Related posts

Leave a Comment